Serum thyroxine and age - rather than thyroid volume and serum TSH - are determinants of the thyroid radioiodine uptake in patients with nodular goiter

S J Bonnema, S Fast, V E Nielsen, H Boel-Jørgensen, P Grupe, P B Andersen, L Hegedüs

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Background: 131I therapy is widely used for treatment of non-toxic goiters. A limitation for this treatment is a low thyroid radioiodine uptake (RAIU), often encountered in these patients. Aim: To estimate the impact of various factors on the thyroid RAIU. Methods: We examined prospectively 170 patients (146 females; age range: 22-87 yrs.) with nodular goiter (median 64 ml, range: 20-464 ml) selected for 131I therapy. Serum TSH was sub-normal in 42.4%. None were treated with anti-thyroid drugs. The thyroid RAIU was determined at 24h and 96h. The goiter volume was measured by ultrasound (n=127), or by magnetic resonance imaging (n=43). Results: The 24h and the 96h RAIU were 34.2±9.8(SD)% (range:11.4-66.0%) and 34.0±10.0% (range:10.5-60.9%), respectively. Sixty-one patients had a 24h RAIU
Original languageEnglish
JournalJournal of Endocrinological Investigation
Volume34
Issue number3
Pages (from-to)52-7
Number of pages6
ISSN0391-4097
DOIs
Publication statusPublished - 2011

Fingerprint

Dive into the research topics of 'Serum thyroxine and age - rather than thyroid volume and serum TSH - are determinants of the thyroid radioiodine uptake in patients with nodular goiter'. Together they form a unique fingerprint.

Cite this